Tags

Type your tag names separated by a space and hit enter

Effects of miR-26a-5p on neuropathic pain development by targeting MAPK6 in in CCI rat models.
Biomed Pharmacother. 2018 Nov; 107:644-649.BP

Abstract

MicroRNA are emerging as significant regulators of neuropathic pain progression. In addition, neuroinflammation contributes a lot to neuropathic pain. miR-26a-5p has been identified as an inflammation-associated miRNA in multiple pathological processes. However, little is known about the biological role of miR-26a-5p in neuroinflammation and neuropathic pain development. Therefore, we aimed to investigate the function of miR-26a-5p in neuropathic pain by establishing a rat model using chronic sciatic nerve injury (CCI). A significant decrease of miR-26a-5p expression was observed in the spinal cord tissues form the CCI rats compared to the control group. Moreover, overexpression of miR-26a-5p significantly repressed neuropathic pain and neuroinflammation in CCI rats. MAPK6 was identified as a direct downstream target gene of miR-26a-5p and confirmed by dual-luciferase reporter assays. As displayed, overexpression of miR-26a-5p greatly reduced MAPK6 levels in vitro and in vivo. Meanwhile, MAPK6 expression and miR-26a-5p were oppositely correlated in CCI rats. Furthermore, up-regulation of MAPK6 obviously reversed the suppressive effect of miR-26a-5p on neuroinflammation and neuropathic pain progression. Taken these together, our results implied that miR-26a-5p could act as a negative regulator of neuropathic pain development through targeting MAPK6, which indicated that miR-26a-5p might serve as a potential therapeutic target for neuropathic pain.

Authors+Show Affiliations

Department of Anesthesiology, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, 223300, PR China.Department of Anesthesiology, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, 223300, PR China.Department of Anesthesiology, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, 223300, PR China.Department of Anesthesiology, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, 223300, PR China.Department of Anesthesiology, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, 223300, PR China.Department of Anesthesiology, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, 223300, PR China.Department of Anesthesiology, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, 223300, PR China. Electronic address: zhang_y1@yeah.net.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

30118880

Citation

Zhang, Yang, et al. "Effects of miR-26a-5p On Neuropathic Pain Development By Targeting MAPK6 in in CCI Rat Models." Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, vol. 107, 2018, pp. 644-649.
Zhang Y, Su Z, Liu HL, et al. Effects of miR-26a-5p on neuropathic pain development by targeting MAPK6 in in CCI rat models. Biomed Pharmacother. 2018;107:644-649.
Zhang, Y., Su, Z., Liu, H. L., Li, L., Wei, M., Ge, D. J., & Zhang, Z. J. (2018). Effects of miR-26a-5p on neuropathic pain development by targeting MAPK6 in in CCI rat models. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 107, 644-649. https://doi.org/10.1016/j.biopha.2018.08.005
Zhang Y, et al. Effects of miR-26a-5p On Neuropathic Pain Development By Targeting MAPK6 in in CCI Rat Models. Biomed Pharmacother. 2018;107:644-649. PubMed PMID: 30118880.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of miR-26a-5p on neuropathic pain development by targeting MAPK6 in in CCI rat models. AU - Zhang,Yang, AU - Su,Zhen, AU - Liu,Hai-Lin, AU - Li,Lin, AU - Wei,Meng, AU - Ge,Dong-Jian, AU - Zhang,Zhi-Jie, Y1 - 2018/08/15/ PY - 2018/05/27/received PY - 2018/08/02/revised PY - 2018/08/03/accepted PY - 2018/8/18/pubmed PY - 2018/12/26/medline PY - 2018/8/18/entrez KW - MAPK6 KW - Neuroinflammation KW - Neuropathic pain KW - miR26a-5p SP - 644 EP - 649 JF - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie JO - Biomed. Pharmacother. VL - 107 N2 - MicroRNA are emerging as significant regulators of neuropathic pain progression. In addition, neuroinflammation contributes a lot to neuropathic pain. miR-26a-5p has been identified as an inflammation-associated miRNA in multiple pathological processes. However, little is known about the biological role of miR-26a-5p in neuroinflammation and neuropathic pain development. Therefore, we aimed to investigate the function of miR-26a-5p in neuropathic pain by establishing a rat model using chronic sciatic nerve injury (CCI). A significant decrease of miR-26a-5p expression was observed in the spinal cord tissues form the CCI rats compared to the control group. Moreover, overexpression of miR-26a-5p significantly repressed neuropathic pain and neuroinflammation in CCI rats. MAPK6 was identified as a direct downstream target gene of miR-26a-5p and confirmed by dual-luciferase reporter assays. As displayed, overexpression of miR-26a-5p greatly reduced MAPK6 levels in vitro and in vivo. Meanwhile, MAPK6 expression and miR-26a-5p were oppositely correlated in CCI rats. Furthermore, up-regulation of MAPK6 obviously reversed the suppressive effect of miR-26a-5p on neuroinflammation and neuropathic pain progression. Taken these together, our results implied that miR-26a-5p could act as a negative regulator of neuropathic pain development through targeting MAPK6, which indicated that miR-26a-5p might serve as a potential therapeutic target for neuropathic pain. SN - 1950-6007 UR - https://www.unboundmedicine.com/medline/citation/30118880/Effects_of_miR_26a_5p_on_neuropathic_pain_development_by_targeting_MAPK6_in_in_CCI_rat_models_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0753-3322(18)33593-5 DB - PRIME DP - Unbound Medicine ER -